Interpace Biosciences Inc 2025年季度报告

ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Interpace Biosciences, Inc.(Exact name of registrant as specified in its charter) (Address of principal executive offices and zip code)(855)776-6419 Securities registered pursuant to Section 12(b) of the Act: with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ ClassShares Outstanding May 2, 2025Common Stock, par value $0.01per share4,423,093 PART I - FINANCIAL INFORMATION (unaudited)Condensed Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2025 and 2024 (unaudited) Controls and Procedures management. The Company develops and commercializes genomic tests and related first line assays principally focused on early detection ofpatients with indeterminate biopsies and at high risk of cancer using the latest technology. The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) Diagnostics Lab Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC), and related notes as included in the Company’sAnnual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities & Exchange Commission (“SEC”) on March 31, 2025 and as amended on April 28, 2025.The Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in theUnited States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, theydo not include all of the information and footnotes required by GAAP for complete financial statements. The Interim Financial Statements TVG, Inc., its Commercial Services business unit, which was sold on December 22, 2015 and its Interpace Pharma Solutions business whichwas sold on August 31, 2022. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three-month period ended March 31, 2025 are not necessarily indicative of the results that may be expected for the fiscal year endingDecember 31, 2025. Note agreement with BroadOak for an additional $2.0million (the “Convertible Note”), which was converted into a subordinated term loan andwas added to the outstanding Term Loan balance. The Term Loan has been subsequently amended. See Note 13,Notes Payable, for moreFurther, along with many laboratories, the Company will be negatively impacted by Local Coverage Determination (“LCD”) L39365, whichwas finalized on April 24, 2025 by our local Medicare Administrative Contractor, Novitas. This LCD, which governs “Genetic Testing forOncology,” resulted in the loss of Medicare coverage for one of our molecular tests, PancraGEN®. On June 5, 2023, the Company announcedthat Novitas issued the final LCD of Genetic Testing for Oncology (L39365) which, if finalized, would have established non-coverage for the undefined extension to the final decision for the LCD. As a result, the Company was able to continue offering PancraGEN®Point2®fluid chemistry tests for amylase, CEA, and glucose for all of 2024. 7 On January 27, 2025, the Company announced that CMS had directed its Medicare Administrative Contractors, Novitas and First Coast ServiceOptions, Inc., to delay implementation of the Genetic Testing for Oncology LCD (L39365), from February 23, 2025 until April 24, 2025. OnApril, 24, 2025, the Company announced that the LCD would take effect immediately and that specimens for first-line fluid chemistry andtesting will not be accepted by the Company after May 2, 2025. On April 25, 2025, the Company announced implementation ofits previously approved Restructuring Plan. The Company expects the implementation of the Restructuring Plan to be substantially completedby the end of the second quarter of 2025.Under the Restructuring Plan, the Company is reducing its workforce and impacted employees will be eligible to receive severance benefits.The Company expects to incur severance costs in the range of $0.5million to $0.6million to be recorded primarily in the second quarter of2025 which is in addition to the $0.2million recorded in the first quarter of 2025. The Company intends to meet its ongoing capital needs by using its available cash, as well as through targeted margin improvement; collectionof accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives. financings, strategic alliances, business development and other sources in order to provide additional liquidity. With the delisting of its commonstock, par value $0.01per share (“Common Stock”), from Nasdaq in February 2021, the Company’s ability to raise additional capital on terms acceptable to it has been advers